Verastem Prices 8.544 Million Share Spot Secondary Offering at $7.25

Written by Emily J. Thompson, Senior Investment Analyst

VSTM-2.19%

Updated: Nov 14 2025

0mins

Correction on Pricing: The deal was priced at $7.25, correcting an earlier report of $8.25.
Underwriters Involved: Jefferies, Guggenheim, and Cantor Fitzgerald served as joint book running managers for the offering.

VSTM

$6.24+Infinity%1D

Analyst Views on VSTM

Wall Street analysts forecast VSTM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VSTM is 15.60 USD with a low forecast of 14.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Analyst Rating

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 6.380

Low

14.00

Averages

15.60

High

20.00

Current: 6.380

Low

14.00

Averages

15.60

High

20.00

Guggenheim

Michael Schmidt

Buy

maintain

$14

2025-12-30

Reason

Guggenheim

Michael Schmidt

Price Target

$14

AI Analysis

2025-12-30

maintain

Buy

Reason

After Verastem announced it will discontinue development of avutometinib/defactinib plus Amgen's (AMGN) sotorasib for KRAS G12C mutant NSCLC and end the RAMP 203 study, Guggenheim analyst Michael Schmidt tells investors that the firm is "not surprised by the announcement" given the RAMP 203 study and the KRAS G12Ci combo opportunity has not been a major investor focus or meaningful component of the stock's valuation. The firm maintains a Buy rating and $14 price target on Verastem shares.

Mizuho

Outperform

maintain

$15

2025-11-04

Reason

Mizuho

Price Target

$15

2025-11-04

maintain

Outperform

Reason

Mizuho reiterated an Outperform rating and $15 price target on Verastem, noting the shares are falling intraday following the company's Q3 results. At first blush, the firm was "thoroughly impressed" by the first full quarterly sales of lead asset Avmapki Fakzynja/AF Co-Pack of $11.2M, which came in handily ahead of the firm's and Bloomberg's consensus estimates. Mizuho said that it believes the stock weakness is related to two updates, namely a need to add 29 additional patients to the confirmatory Phase 3 RAMP 301 study for AF and uncertainty on the timing of AF's potential inclusion in updated National Comprehensive Cancer Network treatment guidelines. The firm added that the current weakness appears overdone and recommends being "opportunistic."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VSTM

Unlock Now

Mizuho

NULL -> Outperform

maintain

$14 -> $15

2025-10-29

Reason

Mizuho

Price Target

$14 -> $15

2025-10-29

maintain

NULL -> Outperform

Reason

Mizuho raised the firm's price target on Verastem to $15 from $14 and keeps an Outperform rating on the shares.

RBC Capital

Outperform

maintain

$13

2025-10-20

Reason

RBC Capital

Price Target

$13

2025-10-20

maintain

Outperform

Reason

RBC Capital keeps an Outperform rating on Verastem with a $13 price target after the company's partner GenFleet Therapeutics reported Phase I/II data for VS-7375 outside of China in advanced pancreatic ductal adenocarcinoma patients with a KRAS G12D mutation. The data show meaningful efficacy in a highly refractory patient population, the analyst tells investors in a research note. The firm says that while VS-7375's response rate of 41% "look best-in-class," they did did decrease somewhat from the prior readout. They data overall are "still impressive," contends RBC. Verastem shares in midday trading are down 13% to $8.01.

About VSTM

Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.